ECU
PCVX icon

Eisler Capital (US)’s Vaxcyte PCVX Stock Holding History

Eisler Capital (US)’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,454
Closed -$789K – 621
2024
Q2 		$789K Hold
10,454
– – 0.01% 524
2024
Q1 		$714K Buy
+10,454
New +$724K 0.02% 435

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eisler Capital (US)'s PCVX Position: Q3 2024 in Review

Eisler Capital (US) sold out of Vaxcyte (PCVX) in Q3 2024, closing a stake of 10,454 shares — an estimated $789K sold.

Eisler Capital (US) first reported a position in PCVX in Q1 2024 and held it in 2 quarters. The position peaked at $789K in Q2 2024. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

  • Eisler Capital (US) reported no remaining Vaxcyte position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 10,454 Vaxcyte shares in Q3 2024, an estimated $789K.
  • Eisler Capital (US) first reported a position in Vaxcyte in Q1 2024 and held it in 2 quarters.
  • Eisler Capital (US)'s Vaxcyte position peaked at $789K in Q2 2024.
  • 328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.